 This is an open-label all people know the identity of the intervention, multi-center study conducted at multiple sites, uncontrolled all the patients receiving darunavir clinical and observational study study in which the investigatorsphysicians observe the patients and measure their outcomes to evaluate the safety and effectiveness of darunavir for the treatment human immunodeficiency virus-type 1 HIV-1 infection among adult Filipino patients. The study will enroll 10 percentage of patient who would use the product, as a requirement of the Philippine Food and Drug Administration FDA. Patients will be monitored from baseline and every 4 weeks thereafter for a period of 24 weeks. Safety evaluations for adverse events, clinical laboratory tests, physical examination, concomitant medications, and co-morbid conditions will be monitored throughout the study. The duration of treatment will be for 24 weeks and the total study will be conducted for 3 years. 